These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39358400)

  • 1. A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.
    Li L; Liu C; Wang R; Yang X; Wei X; Chu C; Zhang G; Liu C; Cui W; Xu H; Wang K; An L; Li X
    Sci Rep; 2024 Oct; 14(1):22895. PubMed ID: 39358400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
    Pang L; Huang Y; Zhuang W; Zhang Y; Liao J; Hao Y; Hao F; Wang G; Chen ZC; Zhu Y; Li M; Song Z; Deng BP; Li J; Zhang L; Fang W
    Clin Cancer Res; 2024 Jun; 30(12):2636-2646. PubMed ID: 38578683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.
    Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X
    Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
    Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
    Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
    Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
    Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.
    Wang R; Cui W; Li L; Wei X; Chu C; Zhang G; Liu C; Xu H; Liu C; Wang K; Li Y; An L
    Chem Biol Interact; 2024 May; 395():111033. PubMed ID: 38710274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
    Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various
    Ito K; Nishio M; Kato M; Murakami H; Aoyagi Y; Ohe Y; Okayama T; Hashimoto A; Ohsawa H; Tanaka G; Nonoshita K; Ito S; Matsuo K; Miyadera K
    Mol Cancer Ther; 2019 May; 18(5):920-928. PubMed ID: 30872380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
    Mittal S; Kamath A; Joseph AM; Rajala MS
    Int J Oncol; 2020 Oct; 57(4):989-1000. PubMed ID: 32945365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.